Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02636582 · ClinicalTrials.gov registry record · Phase 2
Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT02636582: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT02636582 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02636582, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This phase II trial studies how well nelipepimut-S plus GM-CSF vaccine therapy or sargramostim works in treating patients with breast cancer. Vaccines made from peptide or antigen and/or a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells that express breast cancer antigens. It is not yet known whether nelipepimut-S plus GM-CSF vaccine or sargramostim is more effective in treating patients with breast cancer.
Interventions
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Surgical Procedure
- BIOLOGICAL Sargramostim
- DRUG Nelipepimut-S Plus GM-CSF Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2016-06-14 |
| Est. Completion | 2023-05-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02636582
The ClinicalTrials.gov registry entry for NCT02636582 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02636582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02636582 about?
NCT02636582 is a clinical study titled "Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer". This phase II trial studies how well nelipepimut-S plus GM-CSF vaccine therapy or sargramostim works in treating patients with breast cancer. Vaccines made from peptide or antigen and/or a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to ki...
What is the current status of trial NCT02636582?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2016-06-14. Estimated completion is 2023-05-17.
What interventions are being tested in trial NCT02636582?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Surgical Procedure (PROCEDURE), Sargramostim (BIOLOGICAL), Nelipepimut-S Plus GM-CSF Vaccine (DRUG).
Who is sponsoring clinical trial NCT02636582?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.